Trials / Completed
CompletedNCT01057498
Safety Study of Nebulized RNS60 to Treat Asthma.
A Phase I Study of Nebulized RNS60 in Adult Healthy Subjects and Patients With Mild to Moderate Asthma.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Revalesio Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is two-fold. First, to determine whether nebulized RNS60 is safe in healthy human subjects and in subjects with mild asthma, in a single-dose administration. Second, to determine whether nebulized RNS60 is safe in human subjects with mild-to-moderate asthma over a 4-week period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RNS60 | RNS60, 4ml nebulized twice daily for 15 minutes. |
| DRUG | RNS60 - single dose | RNS60, single 4 ml dose nebulized for 15 minutes |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2010-11-01
- Completion
- 2011-01-01
- First posted
- 2010-01-27
- Last updated
- 2012-01-12
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01057498. Inclusion in this directory is not an endorsement.